Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises in conjunction with sale of shares in Embellence Group
Mandate

Vinge advises in conjunction with sale of shares in Embellence Group

December 13, 2021 Capital Markets and Public M&A M&A

Vinge has advised Litorina CoInvest 1 AB in conjunction with the sale of 10.5 percent of the shares and votes in Embellence Group AB (publ) to JCE Asset Management AB.

Embellence Group is a leading European company in the premium wallpaper segment and has a prominent position internationally with sales in over 90 countries. Embellence Group is listed on Nasdaq First North Premier.

Vinge’s team consisted of Johan Winnerblad, Rikard Lindahl and Joel Magnusson.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026